Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Keywords: Coronavirus, main protease, drug design
Current Pharmaceutical Design
Title: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Volume: 12 Issue: 35
Author(s): Haitao Yang, Mark Bartlam and Zihe Rao
Affiliation:
Keywords: Coronavirus, main protease, drug design
Abstract: Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Export Options
About this article
Cite this article as:
Yang Haitao, Bartlam Mark and Rao Zihe, Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses, Current Pharmaceutical Design 2006; 12 (35) . https://dx.doi.org/10.2174/138161206779010369
DOI https://dx.doi.org/10.2174/138161206779010369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery of CRISPR/Cas13 as a Promising Therapeutic Approach to Treat SARS-CoV-2
Current Pharmaceutical Biotechnology Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Abiding by the World Health Organization Guidelines: A Hobson’s Choice
Coronaviruses COVID-19 Effect: Time to Change the Way of Research
Coronaviruses The Effect of Plant Metabolites on Coronaviruses: A Comprehensive Review Focusing on their IC<sub>50</sub> Values and Molecular Docking Scores
Mini-Reviews in Medicinal Chemistry A Perspective of Viruses and the Outbreak of a Novel Coronavirus SARS-CoV- 2
Current Enzyme Inhibition An Overall Picture of SARS Coronavirus (SARS-CoV) Genome-Encoded Major Proteins: Structures, Functions and Drug Development
Current Pharmaceutical Design Machine Intelligence Techniques for the Identification and Diagnosis of COVID-19
Current Medicinal Chemistry siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review
Infectious Disorders - Drug Targets Withdrawal Notice: Emerging Novel Coronavirus is a Global Threat: Insight in the Biology of COVID-19 and its Hijacking Process of Hosts’ Cell
Current Pharmaceutical Design Advances and Challenges in Kidney Organoids
Current Stem Cell Research & Therapy Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections
Current Medicinal Chemistry Inhibition Kinetics of Flavonoids on Yeast α-Glucosidase Merged with Docking Simulations
Protein & Peptide Letters Bioinformatics-Based Characterization of Proteins Related to SARS-CoV- 2 Using the Polarity Index Method<sup>®</sup> (PIM<sup>®</sup>) and Intrinsic Disorder Predisposition
Current Proteomics High Throughput Bioassays Using Nanoparticles
Combinatorial Chemistry & High Throughput Screening Indirect-Acting Pan-Antivirals vs. Respiratory Viruses: A Fresh Perspective on Computational Multi-Target Drug Discovery
Current Topics in Medicinal Chemistry An Overview of the Treatment Contributions Measured Globally for the COVID-19 Outbreak
Coronaviruses Do Genetic Factors Predispose People to COVID-19: A Review Article
Current Molecular Medicine